1,948 Shares in LeMaitre Vascular, Inc. (NASDAQ:LMAT) Purchased by Sanctuary Advisors LLC

Sanctuary Advisors LLC purchased a new stake in LeMaitre Vascular, Inc. (NASDAQ:LMAT) during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm purchased 1,948 shares of the medical instruments supplier’s stock, valued at approximately $181,000.

Other large investors have also recently modified their holdings of the company. Bank of New York Mellon Corp grew its position in LeMaitre Vascular by 2.5% in the second quarter. Bank of New York Mellon Corp now owns 210,599 shares of the medical instruments supplier’s stock worth $17,328,000 after acquiring an additional 5,213 shares in the last quarter. Allspring Global Investments Holdings LLC boosted its holdings in shares of LeMaitre Vascular by 61.3% in the 2nd quarter. Allspring Global Investments Holdings LLC now owns 9,202 shares of the medical instruments supplier’s stock worth $757,000 after purchasing an additional 3,498 shares in the last quarter. Van ECK Associates Corp bought a new position in shares of LeMaitre Vascular during the 2nd quarter valued at about $75,000. nVerses Capital LLC raised its holdings in shares of LeMaitre Vascular by 33.3% during the 2nd quarter. nVerses Capital LLC now owns 800 shares of the medical instruments supplier’s stock valued at $66,000 after buying an additional 200 shares in the last quarter. Finally, Versor Investments LP bought a new stake in LeMaitre Vascular in the 2nd quarter worth approximately $387,000. Institutional investors own 84.64% of the company’s stock.

LeMaitre Vascular Trading Up 0.1 %

LMAT stock opened at $92.95 on Tuesday. The stock has a market capitalization of $2.09 billion, a price-to-earnings ratio of 50.79, a PEG ratio of 2.47 and a beta of 0.93. The firm’s 50-day moving average price is $98.02 and its two-hundred day moving average price is $90.68. LeMaitre Vascular, Inc. has a 12-month low of $52.88 and a 12-month high of $109.58.

LeMaitre Vascular (NASDAQ:LMAT) last released its quarterly earnings results on Thursday, October 31st. The medical instruments supplier reported $0.49 EPS for the quarter, beating analysts’ consensus estimates of $0.44 by $0.05. The business had revenue of $54.82 million during the quarter, compared to analyst estimates of $53.50 million. LeMaitre Vascular had a return on equity of 13.15% and a net margin of 19.40%. LeMaitre Vascular’s quarterly revenue was up 15.6% compared to the same quarter last year. During the same quarter in the prior year, the company posted $0.33 EPS. Equities analysts predict that LeMaitre Vascular, Inc. will post 1.94 EPS for the current year.

LeMaitre Vascular Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Thursday, December 5th. Investors of record on Thursday, November 21st were issued a $0.16 dividend. This represents a $0.64 annualized dividend and a yield of 0.69%. The ex-dividend date of this dividend was Thursday, November 21st. LeMaitre Vascular’s dividend payout ratio (DPR) is currently 34.97%.

Analyst Upgrades and Downgrades

LMAT has been the topic of several research reports. Barrington Research lifted their price target on shares of LeMaitre Vascular from $92.00 to $93.00 and gave the stock an “outperform” rating in a research note on Friday, November 1st. StockNews.com cut shares of LeMaitre Vascular from a “buy” rating to a “hold” rating in a research report on Friday, December 13th. Oppenheimer reissued an “outperform” rating and issued a $93.00 price target (up from $90.00) on shares of LeMaitre Vascular in a research note on Friday, November 1st. Finally, Cantor Fitzgerald began coverage on LeMaitre Vascular in a research note on Tuesday, October 15th. They set a “neutral” rating and a $96.00 price objective on the stock. Three analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $94.57.

Insider Buying and Selling at LeMaitre Vascular

In other LeMaitre Vascular news, Director Bridget A. Ross sold 3,750 shares of the firm’s stock in a transaction on Friday, November 15th. The stock was sold at an average price of $101.47, for a total transaction of $380,512.50. Following the completion of the transaction, the director now owns 2,278 shares of the company’s stock, valued at approximately $231,148.66. This trade represents a 62.21 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Insiders own 10.79% of the company’s stock.

About LeMaitre Vascular

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.